Switching From or To Jardiance (Empagliflozin): Protocols for SGLT2 Inhibitor Class Swaps

How Empagliflozin Works and Why the Mechanism Matters for Switching

Empagliflozin blocks the sodium-glucose cotransporter 2 protein in the S1 segment of the proximal renal tubule, preventing reabsorption of roughly 40% to 80 g of filtered glucose per day 1. That glucose is excreted in the urine, producing an osmotic diuresis and a modest caloric deficit of approximately 200 to 300 kcal daily. Every approved SGLT2 inhibitor (dapagliflozin, canagliflozin, ertugliflozin, and the combination agents sotagliflozin and bexagliflozin) targets this identical transporter.

Because the mechanism is shared, a within-class switch does not introduce a new pharmacologic pathway. The differences between agents are pharmacokinetic, not pharmacodynamic. Empagliflozin has a plasma half-life of 12.4 hours 2, compared to 12.9 hours for dapagliflozin and 10.6 to 13.1 hours for canagliflozin. These similar half-lives mean that stopping one drug on Day 0 and starting another on Day 1 yields near-continuous SGLT2 inhibition with no clinically meaningful gap.

This is different from switching between drug classes. Moving a patient from a DPP-4 inhibitor to an SGLT2 inhibitor, for example, activates an entirely separate glucose-lowering pathway and may require more careful titration and monitoring.

Dose Mapping: Empagliflozin to Other SGLT2 Inhibitors

The FDA-approved doses for each SGLT2 inhibitor do not follow a uniform numbering scheme, which can confuse both patients and prescribers. The table below provides approximate equivalence based on HbA1c-lowering data pooled across key trials 3.

Empagliflozin 10 mg (Jardiance starting dose) maps to dapagliflozin 10 mg (Farxiga) and canagliflozin 100 mg (Invokana). Empagliflozin 25 mg (the higher approved dose for T2D) maps roughly to canagliflozin 300 mg; dapagliflozin does not have a higher glycemic dose, since 10 mg is its ceiling for type 2 diabetes.

For heart failure, empagliflozin 10 mg and dapagliflozin 10 mg are both approved at a single dose level 4. No uptitration is needed for either agent when heart failure is the indication. A prescriber switching a heart failure patient from dapagliflozin 10 mg to empagliflozin 10 mg can do so at a 1:1 ratio.

For chronic kidney disease, the EMPA-KIDNEY trial used empagliflozin 10 mg 5 and DAPA-CKD used dapagliflozin 10 mg 6. Again, a 1:1 swap applies. Canagliflozin's CKD dose (tested in CREDENCE) was 100 mg daily 7.

When and Why Clinicians Switch SGLT2 Inhibitors

Formulary pressure drives most within-class switches. A 2023 analysis of U.S. commercial claims found that 68% of SGLT2-to-SGLT2 switches were initiated after a formulary change or prior authorization denial 8. The 2024 ADA Standards of Care note that "within a drug class, if a specific medication is not available or tolerated, substitution with another agent in the same class is appropriate" 9.

Side-effect profiles provide a second reason. Canagliflozin carries a boxed warning history for lower-limb amputations identified in the CANVAS program (6.3 vs. 3.4 per 1,000 patient-years) 10, although the FDA later removed the boxed warning after broader data review. Some clinicians still preferentially switch peripheral arterial disease patients from canagliflozin to empagliflozin or dapagliflozin.

A third reason: organ-specific outcome data. EMPA-REG OUTCOME demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin versus placebo (3.7% vs. 5.9%; HR 0.62 to 95% CI 0.49 to 0.77) in patients with type 2 diabetes and established cardiovascular disease 1. For a patient already on dapagliflozin who develops atherosclerotic cardiovascular disease, some cardiologists favor empagliflozin based on this dataset. The 2022 AHA/ACC/HFSA heart failure guidelines state that "SGLT2 inhibitors have a class I recommendation for HFrEF regardless of diabetes status" but do not prefer one agent over another 11.

Step-by-Step Switching Protocol

The switch itself is straightforward. Stop the outgoing SGLT2 inhibitor after the last evening or morning dose. Start the incoming agent the following morning with or without food. No washout is needed.

Dr. Silvio Inzucchi, director of the Yale Diabetes Center and a lead EMPA-REG OUTCOME investigator, has stated: "There is no pharmacologic rationale for a washout between SGLT2 inhibitors. These drugs share a target, and the transition can be smooth when dose equivalence is maintained" 1.

Pre-switch checklist:

1. Confirm the new agent's approved indication matches the patient's treatment goal (T2D, HF, CKD).
2. Check eGFR. Empagliflozin's glycemic efficacy diminishes below eGFR 30 mL/min/1.73 m², though cardio-renal benefits persist 5. Dapagliflozin has a similar eGFR floor. If eGFR has declined since the last agent was started, reassess whether the switch still provides benefit for the target indication.
3. Review concurrent medications. Insulin and sulfonylurea doses may need reduction if the new SGLT2 inhibitor has marginally different glycemic potency (rare within class, but worth verifying).
4. Counsel on genital mycotic infection risk, which is a class effect occurring in 5% to 10% of women and 3% to 5% of men across all SGLT2 inhibitors 2.

Post-switch monitoring:

Recheck serum creatinine and electrolytes at 2 to 4 weeks. An initial eGFR dip of 10% to 15% is expected with any SGLT2 inhibitor initiation and reflects hemodynamic changes in glomerular pressure, not structural kidney damage 12. This dip may re-emerge slightly on the new agent. Repeat HbA1c at 3 months if glycemia is the treatment target.

Switching From a Different Drug Class to Empagliflozin

Moving from a DPP-4 inhibitor (sitagliptin, linagliptin, saxagliptin, alogliptin) to empagliflozin involves replacing one oral agent with another. No overlap period is needed; however, the mechanisms differ substantially. DPP-4 inhibitors augment incretin-mediated insulin secretion. SGLT2 inhibitors are insulin-independent. Patients should be told that increased urination is expected and is the drug working as intended.

The 2024 ADA consensus algorithm recommends SGLT2 inhibitors over DPP-4 inhibitors when a patient has established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease 9. For patients on combination therapy with metformin plus a DPP-4 inhibitor, the DPP-4 inhibitor can be stopped and empagliflozin started immediately.

For patients switching from a GLP-1 receptor agonist to empagliflozin (or adding empagliflozin on top), the two classes are complementary. The DURATION-8 trial showed that exenatide plus dapagliflozin produced a 2.0% HbA1c reduction versus 1.4% with either agent alone 13. Many patients now use an SGLT2 inhibitor alongside a GLP-1 RA rather than switching.

Patients transitioning off sulfonylureas (glimepiride, glipizide) to empagliflozin should be counseled that hypoglycemia risk drops, because SGLT2 inhibitors do not stimulate insulin secretion. The sulfonylurea can be discontinued on Day 0 with empagliflozin started on Day 1, but blood glucose should be monitored more frequently for the first week given the change in glycemic mechanism.

Special Populations: Heart Failure and CKD Switches

In the EMPEROR-Reduced trial, empagliflozin 10 mg reduced the composite of cardiovascular death or heart failure hospitalization by 25% (HR 0.75 to 95% CI 0.65 to 0.86; P<0.001) compared with placebo in HFrEF patients 4. In EMPEROR-Preserved, the same dose reduced the same endpoint by 21% (HR 0.79 to 95% CI 0.69 to 0.90) in HFpEF patients 14.

The 2022 AHA/ACC/HFSA guideline writing committee noted: "For patients with HF, we recommend SGLT2 inhibitors regardless of the presence or absence of T2D. Evidence supports both dapagliflozin and empagliflozin" 11. A heart failure patient stable on dapagliflozin 10 mg who must switch for formulary reasons can transition to empagliflozin 10 mg without dose adjustment.

For CKD, EMPA-KIDNEY enrolled 6,609 patients with eGFR 20 to 45 (or 45 to 90 with urine albumin-to-creatinine ratio of 200 mg/g or higher) and showed a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82) 5. Switching a CKD patient from canagliflozin 100 mg (the CREDENCE dose) to empagliflozin 10 mg is appropriate at a 1:1 level of SGLT2 inhibition. Monitor volume status closely if the patient also takes a loop diuretic; the osmotic diuresis profile varies mildly between agents.

Euglycemic DKA Risk During Switching

Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious class effect of all SGLT2 inhibitors, occurring at a rate of approximately 0.1% per year in type 2 diabetes trials 15. The risk does not reset upon switching within class, but certain perioperative or illness-related triggers deserve extra attention during any medication transition.

Current FDA labeling for all SGLT2 inhibitors recommends stopping the drug at least 3 days before scheduled surgery (4 days for ertugliflozin given its longer half-life) 2. If a switch is planned around a surgical date, the simplest approach is to pause the outgoing agent per surgical hold guidelines, undergo the procedure, and start the new SGLT2 inhibitor 3 days postoperatively once oral intake is stable.

Patients should report nausea, vomiting, or abdominal pain occurring during the first week of any new SGLT2 inhibitor. Check point-of-care blood ketones (beta-hydroxybutyrate) if euDKA is suspected; a serum bicarbonate below 18 mmol/L with elevated ketones warrants emergency evaluation regardless of blood glucose level.

What the Evidence Does Not Support

There is no trial evidence showing that rotating between SGLT2 inhibitors improves outcomes beyond what a single agent provides. A practice sometimes informally called "SGLT2 cycling" has no basis in the pharmacology. If a patient is not meeting treatment targets on empagliflozin 25 mg, switching to dapagliflozin 10 mg is unlikely to change the HbA1c trajectory, because the maximal glucose-lowering ceiling is similar across the class.

The better clinical move in that scenario is to add a complementary mechanism: a GLP-1 receptor agonist, insulin, or (for heart failure patients) optimized neurohormonal blockade with sacubitril/valsartan and mineralocorticoid receptor antagonists. SGLT2 inhibitors are one pillar, not the entire structure.